Latest News Releases From The Newsroom
Pfizer's RSV Vaccine Approval, Victoria's Secret Misses Estimates, nCino and PVH Surpass Expectations: Stock Market Recap
June 01st, 2023
Pfizer Inc. (NYSE: PFE), a global pharmaceutical company specializing in vaccines and medicines, announced that its bivalent RSV prefusion F (RSVpreF) vaccine, ABRYSVO, has received approval from the U.S. Food and Drug Administration (FDA). . Read more
Xylem, Liberty Latin America, Saga Communications, Telefonica Brasil, Terns Pharma, NICE: Analyst Ratings and Price Targets Hint at Potential Upsides
June 01st, 2023
Xylem Inc. (NYSE: XYL) has received an upgrade from Neutral to Outperform by Robert W. Baird, with the price target raised from $122 to $135. On Wednesday, $XYL closed at $100.20, indicating a potential upside of $34.80 or 34.72% based on th. Read more
Promising Findings from HOOKIPA's HPV16+ Head and Neck Cancer Study; Chewy Beats Estimates, C3.ai Revenue Outlook Disappoints
June 01st, 2023
HOOKIPA Pharma Inc. (Nasdaq: HOOK) has released promising preliminary data from its Phase 2 study of HB-200 in combination with pembrolizumab, offering hope for patients with recurrent/metastatic Human Papillomavirus 16-positive (HPV16+) head and nec. Read more
FTC and DOJ Charge Amazon with Violating Children’s Privacy Law by Keeping Kids’ Alexa Voice Recordings Forever and Undermining Parents’ Deletion Requests
May 31st, 2023
Proposed order to require Amazon to pay $25 million and delete children’s data, geolocation data, and other voice recordings Washington D.C. / CRWE PRESS RELEASE / May 31, 2023 - The Federal Trade Commission and the Department of. Read more
Chevron, Nevro, America Movil, Hillman Solutions, Grupo Televisa, and ACNB - Assessing Potential Upside and Price Targets
May 31st, 2023
Chevron Corporation (NYSE: CVX), a multinational energy corporation, has been upgraded from Underweight to Neutral by JP Morgan. The price target for $CVX has also been raised from $161 to $170 based on the firm's view. On Wednesday, $CV. Read more
Akebia Therapeutics, MDxHealth, Avis Budget, argenx, Five9, Inventiva: Analyst Upgrades and Initiations Point to Potential Upsides
May 31st, 2023
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company, received an upgrade from Neutral to Overweight by Piper Sandler, with the price target raised from $2 to $4. On Wednesday, $AKBA closed at $1.04, indicating a potential u. Read more
Better-Than-Expected Results: Nordstrom and NetApp Thrive, Okta and Salesforce Encounter Market Headwinds
May 31st, 2023
Nordstrom, Inc. (NYSE: JWN), a renowned fashion retailer with a presence in the United States and Canada, reported first quarter 2023 adjusted earnings per share (EPS) of $0.07, surpassing the consensus estimate of a loss of $0.08 per share. . Read more
FDA Conducts Retailer Inspection Blitz, Cracks Down on Illegal Sales of Popular Disposable E-cigarettes
May 31st, 2023
Washington D.C. / CRWE PRESS RELEASE / May 31, 2023 - Today, the U.S. Food and Drug Administration issued warning letters to 30 retailers, including one distributor, for illegally selling unauthorized tobacco products. The unauth. Read more
Pre-Market Movers: Marker Therapeutics Surges on MT-601 Potential, Trevena on Milestone Payment
May 31st, 2023
Marker Therapeutics, Inc. (Nasdaq: MRKR) shared positive pre-clinical data regarding their T cell product candidate, MT-601, which targets multiple tumor-associated antigens (multiTAA) in lymphoma cells, including those resistant to CD19 CAR T cell t. Read more
Advance Auto Parts Q1 Results Fall Short of Consensus, Lowers Outlook; iRhythm Technologies Reveals FDA Warning Letter
May 31st, 2023
The first quarter of 2023 proved to be challenging for Advance Auto Parts, Inc. (NYSE: AAP), as the company reported diluted earnings per share (EPS) of $0.72, falling short of the consensus estimate of $2.57. Tom Greco, the president and ch. Read more
Want To Find Some News?
News By Industries
Recent Posts
-
June 03rd, 2023June 02nd, 2023June 02nd, 2023